Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NuVasive stock | 45.57

Own NuVasive stock in just a few minutes.

Posted

Fact checked

NuVasive, Inc is a medical devices business based in the US. NuVasive shares (NUVA) are listed on the NASDAQ and all prices are listed in US Dollars. NuVasive employs 2,800 staff and has a trailing 12-month revenue of around USD$1.1 billion.

How to buy shares in NuVasive

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for NuVasive. Find the stock by name or ticker symbol: NUVA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NuVasive reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$45.57, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NuVasive, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of NuVasive. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted NuVasive's share price?

Since the stock market crash in March caused by coronavirus, NuVasive's share price has had significant negative movement.

Its last market close was USD$45.57, which is 39.37% down on its pre-crash value of USD$75.16 and 59.61% up on the lowest point reached during the March crash when the shares fell as low as USD$28.55.

If you had bought USD$1,000 worth of NuVasive shares at the start of February 2020, those shares would have been worth USD$518.72 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$588.31.

NuVasive share price

Use our graph to track the performance of NUVA stocks over time.

NuVasive shares at a glance

Information last updated 2020-10-20.
Latest market close USD$45.57
52-week range USD$28.55 - USD$81.91
50-day moving average USD$51.6094
200-day moving average USD$55.6476
Wall St. target price USD$65.88
PE ratio 49.687
Dividend yield N/A (0%)
Earnings per share (TTM) USD$1.147

Buy NuVasive shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NuVasive stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NuVasive price performance over time

Historical closes compared with the close of $45.57 from 2020-11-16

1 week (2020-11-13) -4.33%
1 month (2020-10-23) -12.97%
3 months (2020-08-21) -13.22%
6 months (2020-05-22) -27.48%
1 year (2019-11-22) -35.89%
2 years (2018-11-21) -27.92%
3 years (2017-11-22) -19.13%
5 years (2015-11-20) -11.34%

Is NuVasive under- or over-valued?

Valuing NuVasive stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NuVasive's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NuVasive's P/E ratio

NuVasive's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, NuVasive shares trade at around 50x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

NuVasive's PEG ratio

NuVasive's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.5972. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NuVasive's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

NuVasive's EBITDA

NuVasive's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$184.4 million.

The EBITDA is a measure of a NuVasive's overall financial performance and is widely used to measure a its profitability.

NuVasive financials

Revenue TTM USD$1.1 billion
Operating margin TTM 5.32%
Gross profit TTM USD$855.7 million
Return on assets TTM 1.59%
Return on equity TTM -0.44%
Profit margin -0.36%
Book value $17.461
Market capitalisation USD$2.7 billion

TTM: trailing 12 months

Shorting NuVasive shares

There are currently 5.9 million NuVasive shares held short by investors – that's known as NuVasive's "short interest". This figure is 7.7% down from 6.4 million last month.

There are a few different ways that this level of interest in shorting NuVasive shares can be evaluated.

NuVasive's "short interest ratio" (SIR)

NuVasive's "short interest ratio" (SIR) is the quantity of NuVasive shares currently shorted divided by the average quantity of NuVasive shares traded daily (recently around 755520.92426187). NuVasive's SIR currently stands at 7.79. In other words for every 100,000 NuVasive shares traded daily on the market, roughly 7790 shares are currently held short.

However NuVasive's short interest can also be evaluated against the total number of NuVasive shares, or, against the total number of tradable NuVasive shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NuVasive's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 NuVasive shares in existence, roughly 110 shares are currently held short) or 0.177% of the tradable shares (for every 100,000 tradable NuVasive shares, roughly 177 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NuVasive.

Find out more about how you can short NuVasive stock.

NuVasive share dividends

We're not expecting NuVasive to pay a dividend over the next 12 months.

NuVasive share price volatility

Over the last 12 months, NuVasive's shares have ranged in value from as little as $28.55 up to $81.91. A popular way to gauge a stock's volatility is its "beta".

NUVA.US volatility(beta: 1.28)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuVasive's is 1.2763. This would suggest that NuVasive's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

NuVasive overview

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprises products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons to access the spine to perform restorative and fusion procedures in a minimally disruptive fashion. The company's biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty and gel. Its IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also provides implants used for interbody disc height restoration; and fixation products, including pedicle screws, rods, and plates. In addition, it offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and Precice, a limb lengthening system. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site